Novo Nordisk Battles Wegovy/Ozempic Pretenders and Faces Mounjaro’s Superior Study Results
Novo Nordisk has filed complaints against two Florida-based compounding pharmacies for marketing unapproved versions of its semaglutide products, claiming the products are weaker in strength than labeling indicates and may contain up to 33 percent impurities.
The company says its semaglutide products are the only FDA-approved products using the “foundational molecule” for the three prescription-only medicines — injectable Wegovy for weight loss, injectable Ozempic for type 2 diabetes and tablet-form Rybelsus for type 2 diabetes — and neither are there any FDA-approved generics, nor does the company sell its semaglutide active pharmaceutical ingredient to any compounding pharmacies.
At the same time, Novo Nordisk faces a challenge from Eli Lilly’s Mounjaro (tirzepatide) after a report by Truveta Research, a healthcare data research company, showed that those taking tirzepatide were “1.8 times more likely than those taking semaglutide to achieve 5 percent weight loss, 6 times more likely than those taking semaglutide to achieve 10 percent weight loss, and three times more likely than those taking semaglutide to achieve 15 percent weight loss. Truveta said it used data from 18,000 patients to compare the effectiveness of the two drugs.
To read the whole story, click here to subscribe.